{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:25:48Z","timestamp":1780061148719,"version":"3.54.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11495-3","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:09:32Z","timestamp":1741367372000},"page":"5771-5780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients"],"prefix":"10.1007","volume":"35","author":[{"given":"Bel\u00e9n","family":"Saborido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Garc\u00eda-Criado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Vilana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Reig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1814-4198","authenticated-orcid":false,"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"11495_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6","journal-title":"Nat Rev Dis Primers"},{"key":"11495_CR2","doi-asserted-by":"crossref","unstructured":"Singal AG, Zhang E, Narasimman M, Nahon P, Parikh ND, Marrero JA (2022) HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis : a meta-analysisJournal of Hepatology. J Heptol 77:128\u2013139","DOI":"10.1016\/j.jhep.2022.01.023"},{"key":"11495_CR3","doi-asserted-by":"crossref","unstructured":"Galle PR, Forner A, Llovet JM et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinomajournal of hepatology. J Heptol 69:182\u2013236","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"11495_CR4","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78:1922\u20131965","journal-title":"Hepatology"},{"key":"11495_CR5","doi-asserted-by":"publisher","first-page":"e232624","DOI":"10.1148\/radiol.232624","volume":"311","author":"M Mendiratta-Lala","year":"2024","unstructured":"Mendiratta-Lala M, Fetzer D, Kamaya A, Parikh ND, Singal AG (2024) The future role of abdominal US in hepatocellular carcinoma surveillance. Radiology 311:e232624","journal-title":"Radiology"},{"key":"11495_CR6","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1007\/s00330-020-07457-6","volume":"31","author":"A Darnell","year":"2021","unstructured":"Darnell A, Rimola J, Belmonte E et al (2021) Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules <\/= 2 cm in cirrhotic patients. Eur Radiol 31:4794\u20134803","journal-title":"Eur Radiol"},{"key":"11495_CR7","doi-asserted-by":"publisher","unstructured":"Lee S, Kim YY, Shin J, Shin H, Sirlin CB, Chernyak V (2024) Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-024-10813-5","DOI":"10.1007\/s00330-024-10813-5"},{"key":"11495_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1148\/radiol.2021211244","volume":"302","author":"CB van der Pol","year":"2022","unstructured":"van der Pol CB, McInnes MDF, Salameh JP et al (2022) CT\/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: individual patient data meta-analysis. Radiology 302:326\u2013335","journal-title":"Radiology"},{"key":"11495_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/HEP.0000000000000558","volume":"79","author":"A Lyshchik","year":"2024","unstructured":"Lyshchik A, Wessner CE, Bradigan K et al (2024) Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe. Hepatology 79:380\u2013391","journal-title":"Hepatology"},{"key":"11495_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00261-019-02181-2","volume":"45","author":"J Hu","year":"2020","unstructured":"Hu J, Bhayana D, Burak KW, Wilson SR (2020) Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY) 45:123\u2013133","journal-title":"Abdom Radiol (NY)"},{"key":"11495_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00261-019-02132-x","volume":"45","author":"HJ Kang","year":"2020","unstructured":"Kang HJ, Kim JH, Joo I, Han JK (2020) Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (\u22652 cm) of CT\/MRI for high-risk patients: focusing on the CT\/MRI LI-RADS categories LR-3 and LR-4. Abdom Radiol (NY) 45:55\u201363","journal-title":"Abdom Radiol (NY)"},{"key":"11495_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816\u2013830","journal-title":"Radiology"},{"key":"11495_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00261-017-1392-0","volume":"43","author":"A Lyshchik","year":"2018","unstructured":"Lyshchik A, Kono Y, Dietrich CF et al (2018) Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY) 43:861\u2013879","journal-title":"Abdom Radiol (NY)"},{"key":"11495_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-0042-124369","volume":"38","author":"Y Kono","year":"2017","unstructured":"Kono Y, Lyshchik A, Cosgrove D et al (2017) Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS(R)): the official version by the American College of Radiology (ACR). Ultraschall Med 38:85\u201386","journal-title":"Ultraschall Med"},{"key":"11495_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1055\/s-0042-124661","volume":"38","author":"F Piscaglia","year":"2017","unstructured":"Piscaglia F, Wilson SR, Lyshchik A et al (2017) American College of Radiology contrast enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) for the diagnosis of hepatocellular carcinoma: a pictorial essay. Ultraschall Med 38:320\u2013324","journal-title":"Ultraschall Med"},{"key":"11495_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00261-017-1250-0","volume":"43","author":"SR Wilson","year":"2018","unstructured":"Wilson SR, Lyshchik A, Piscaglia F et al (2018) CEUS LI-RADS: algorithm, implementation, and key differences from CT\/MRI. Abdom Radiol (NY) 43:127\u2013142","journal-title":"Abdom Radiol (NY)"},{"key":"11495_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2014.08.028","volume":"62","author":"A Forner","year":"2015","unstructured":"Forner A, Vilana R, Bianchi L et al (2015) Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <\u20092 cm. J Hepatol 62:150\u2013155","journal-title":"J Hepatol"},{"key":"11495_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jhep.2017.11.007","volume":"68","author":"E Terzi","year":"2018","unstructured":"Terzi E, Iavarone M, Pompili M et al (2018) Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol 68:485\u2013492","journal-title":"J Hepatol"},{"key":"11495_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/jum.16183","volume":"42","author":"J Hu","year":"2023","unstructured":"Hu J, Burrowes DP, Caine BA et al (2023) Nodules identified on surveillance ultrasound for HCC: CEUS or MRI as the initial test? J Ultrasound Med 42:1181\u20131190","journal-title":"J Ultrasound Med"},{"key":"11495_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1148\/radiol.2019191086","volume":"294","author":"JY Huang","year":"2020","unstructured":"Huang JY, Li JW, Lu Q et al (2020) Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for hepatocellular carcinoma. Radiology 294:329\u2013339","journal-title":"Radiology"},{"key":"11495_CR21","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1007\/s00330-021-07872-3","volume":"31","author":"D Strobel","year":"2021","unstructured":"Strobel D, Jung EM, Ziesch M et al (2021) Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS\u00ae\/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study. Eur Radiol 31:7614\u20137625","journal-title":"Eur Radiol"},{"key":"11495_CR22","doi-asserted-by":"publisher","unstructured":"Kono Y, Piscaglia F, Wilson SR et al (2024) Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT\/MRI in patients at risk for HCC. Abdom Radiol (NY) https:\/\/doi.org\/10.1007\/s00261-024-04305-9","DOI":"10.1007\/s00261-024-04305-9"},{"key":"11495_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ultrasmedbio.2019.12.021","volume":"46","author":"SR Wilson","year":"2020","unstructured":"Wilson SR, Burns PN, Kono Y (2020) Contrast-enhanced ultrasound of focal liver masses: a success story. Ultrasound Med Biol 46:1059\u20131070","journal-title":"Ultrasound Med Biol"},{"key":"11495_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3350\/cmh.2017.0037","volume":"23","author":"TK Kim","year":"2017","unstructured":"Kim TK, Noh SY, Wilson SR et al (2017) Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT\/MRI system. Clin Mol Hepatol 23:280\u2013289","journal-title":"Clin Mol Hepatol"},{"key":"11495_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1148\/radiol.14131963","volume":"272","author":"MS Davenport","year":"2014","unstructured":"Davenport MS, Khalatbari S, Liu PS et al (2014) Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology 272:132\u2013142","journal-title":"Radiology"},{"key":"11495_CR26","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.12998\/wjcc.v8.i22.5589","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Chen M, Wang ZJ et al (2020) Interobserver agreement for contrast-enhanced ultrasound of liver imaging reporting and data system: a systematic review and meta-analysis. World J Clin Cases 8:5589\u20135602","journal-title":"World J Clin Cases"},{"key":"11495_CR27","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/hep.32494","volume":"76","author":"J Rimola","year":"2022","unstructured":"Rimola J, Sapena V, Brancatelli G et al (2022) Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology 76:1318\u20131328","journal-title":"Hepatology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11495-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:12:34Z","timestamp":1757142754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11495-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["11495"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11495-3","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Jordi Rimola.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: B.S. is supported by a grant from Eu Commission. A.D. and A.F. reports lecture fees from Bayer, Boston Science, Gilead, and MSD, consultancy fees from Bayer, Astra Zeneca, Roche, SIRTEX, AB Exact Science, and Guerbert. A.G.-C., A.S., A.D., C.A., R.V., and J.B. has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi and UniversalDX; and received research\/educational grants from Bayer, and lecture fees from Bayer-Shering Pharma, BTGBiocompatibles, Eisai, Terumo, Sirtex, Ipsen. M.R. reports consultancy from Bayer, BMS, Roche, Ipsen, Astra Zeneca, Boston Science, and Lilly; lecture fees from Bayer, BMS, Gilead, Lilly, Roche, and UniversalDX and travel support from Bayer, BMS, Lilly, and Astra Zeneca. Received research funding (to institution) from Bayer and Ipsen. J.R. has received consulting and\/or speaking fees from Roche, Universal Dx, AstraZeneca, and travel grants from Bayer. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained (HCB\/2019\/1021).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have been previously reported in Darnell et al []. The results of the current and previous studies do not overlap.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}